SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Charles River Laboratories International, Inc.
CRL
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
Last trade$333.90
Day change-$1.62 (-0.48%)
Day range$330.99 – $341.25
Volume355,778
Market cap$16.08B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$16.08B
Price / earnings
400.06×
Price / book
4.98×
Price / sales
4.04×
EV / sales
4.61×
EV / EBITDA
22.34×
Profitability
Earnings per share
$0.84
Return on assets
0.54%
Return on equity
1.25%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.76×
Current ratio
1.41×
Quick ratio
1.12×
Cash ratio
0.18×
Cash flow
Price / cash flow
25.83×
Price / free cash flow
59.67×
Free cash flow
$269.43M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CRL, quarterly periods
Line item
Q3 FY2026 Sep 26, 2026
Q2 FY2026 Jun 27, 2026
Q1 FY2026 Mar 28, 2026
Q4 FY2025 Dec 27, 2025
Q3 FY2025 Sep 27, 2025
Q2 FY2025 Jun 28, 2025
Q1 FY2025 Mar 29, 2025
Q4 FY2024 Dec 28, 2024
Revenue
$982.73M
$1B
$995.83M
$994.23M
$1B
$1.03B
$984.17M
$1B
Cost of revenue
$624.86M
$640.7M
$701.17M
$684.54M
$666.06M
$675.07M
$666.44M
$718.31M
Gross profit
$357.87M
$363.37M
$294.66M
$309.68M
$338.79M
$357.07M
$317.73M
$284.24M
Selling, general and administrative
$140.59M
$228.9M
$159.42M
$196.14M
$177.59M
$191.55M
$177.8M
$195.71M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$155.23M
$243.49M
$174.77M
$593.12M
$204.99M
$256.93M
$243.06M
$451.93M
Operating income
$202.64M
$119.89M
$119.9M
-$283.44M
$133.8M
$100.13M
$74.67M
-$167.69M
Interest expense
-$28.53M
-$30.34M
-$26.74M
-$23.78M
-$25.4M
-$29.97M
-$27.88M
-$28.23M
Income before taxes
$170.66M
$53.17M
-$29.94M
-$294.1M
$87.2M
$71.42M
$35.98M
-$216.79M
Income taxes
-$163.79M
$53.93M
-$15.14M
-$17.81M
$31.64M
$18.73M
$10.1M
-$3.04M
Net income
$334.44M
-$760K
-$14.8M
-$276.29M
$55.56M
$52.69M
$25.88M
-$213.75M
Net income attributable to common shareholders
$333.07M
-$1.48M
-$14.84M
-$276.56M
$54.42M
$52.33M
$25.47M
-$215.7M
EBITDA
$274.9M
$187.18M
$187.05M
$170.81M
$218.96M
$219.64M
$195.03M
$149.42M
Basic earnings per share
$6.97
-$0.03
-$0.30
-$5.62
$1.11
$1.06
$0.50
-$4.22
Diluted earnings per share
$6.86
-$0.03
-$0.30
-$5.68
$1.10
$1.06
$0.50
-$4.21
Recent news
Company coverage with links to the original publishers.
GMR Solutions Inc. (GMRS) is positioned as a better value investment compared to Charles River Laboratories (CRL). GMRS holds a Zacks Rank #1 (Strong Buy) with a Value grade of A, featuring a forward P/E of 6.48 and PEG ratio of 0.16, while CRL has a Zacks Rank #3 (Hold) with a Value grade of C, featuring a forward P/E of 30.05 and PEG ratio of 3.11.
Charles River Laboratories (CRL) is highlighted as a strong momentum stock with a #3 Hold rating and B-rated VGM and Momentum Style Scores. The stock has gained 11.8% over the past four weeks, with seven analysts revising earnings estimates higher in the last 60 days. The Zacks Consensus Estimate increased to $11.38 per share, and the company boasts a +5.6% average earnings surprise.
Charles River Laboratories (CRL) reported third-quarter 2026 adjusted EPS of $3.09, up 27.2% year-over-year and beating consensus estimates. The company raised its full-year 2026 revenue and adjusted EPS guidance, with organic revenue growth returning for the second consecutive quarter. Strong performance in DSA and Manufacturing Solutions offset weakness in RMS, while gross and operating margins expanded significantly.
Revvity reported Q3 2026 earnings of $1.38 per share, beating consensus estimates of $1.29, with revenues of $709.61 million slightly exceeding expectations. The company has outperformed the market by 56.7% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market. The Medical Services industry ranks in the top 40% of Zacks industries.
Charles River Laboratories is expected to report Q3 2026 results on November 4 with 22.6% EPS growth despite a projected 4.8% revenue decline. The RMS segment faces weak academic demand but benefits from stronger China demand, while DSA shows improving biopharmaceutical demand with strong booking trends. Manufacturing Solutions is supported by Microbial Solutions strength, though recent divestitures will impact overall growth rates.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.